Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255305 · ClinicalTrials.gov registry record · Phase 2
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
A Phase 2 study, sponsored by Endeavor Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02255305 is a Phase 2 study that was terminated before completion, run by Endeavor Health. The registered enrollment target is 6 participants.
The verdict
NCT02255305, a Phase 2 study, was terminated before completion, sponsored by Endeavor Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI) as compared to standard antibiotic therapy. Patients who have tested positive for CDI within 90 days of an admission for relapse of CDI will be approached to participate in this open-label, randomized controlled trial. Patients will either be randomized to the intervention group (receive FMT via retention enema) or the control group (receive antimicrobials targeting CDI).
Interventions
- BIOLOGICAL FMT
- DRUG Antimicrobials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-01 |
| Est. Completion | 2020-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255305
The ClinicalTrials.gov registry entry for NCT02255305 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FMT is the first listed.
NCT02255305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255305 about?
NCT02255305 is a clinical study titled "FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI". The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI) as compared to standard antibiotic therapy. Patients who have tested positive for CDI within 90 days of an admission for ...
What is the current status of trial NCT02255305?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-01. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02255305?
The interventions under investigation include: FMT (BIOLOGICAL), Antimicrobials (DRUG).
Who is sponsoring clinical trial NCT02255305?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.